Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: A 4-year prospective study

Experimental and Clinical Transplantation

Volumn 9, Issue 1, 2011, Pages 42-49

  Han, Fei ^a   Wu, Jianyong ^a   Huang, Hongfeng ^a   Zhang, Xiaohui ^a   He, Qiang ^a   Wang, Yimin ^a   Wang, Suya ^a   Wang, Huiping ^a   Chen, Jianghua ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Cyclosporine; Glomerular filtration rate; Kidney transplant; Sirolimus; Survival

Indexed keywords

CREATININE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; INFECTION; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; OPEN STUDY; OUTCOME ASSESSMENT; PNEUMONIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL GRAFT DYSFUNCTION; TREATMENT DURATION;

ADULT; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CHINA; CHRONIC DISEASE; CREATININE; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 79952664485     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349(24):2326-2333.
2. Woolfson RG, Neild GH. Cyclosporin nephrotoxicity following cardiac transplantation. Nephrol Dial Transplant. 1997;12(10):2054-2056.
3. Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the creeping creatinine study. Transplantation. 2005;79(4):466-475.
4. Oberbauer R, Kreis H, Johnson RW, et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation. 2003;76(2):364-370.
5. Watson CJ, Firth J, Williams PF, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant. 2005;5(10):2496-2503.
6. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant. 2004;4(11):1869-1875.
7. Bumbea V, Kamar N, Ribes D, et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant. 2005;20(11):2517-2523.
8. Chen D, Zhang WJ, Chen ZS, et al. Risk factor of long-term anemia in kidney transplantation receptors [in Chinese]. J Clin Surg. 2008;16(8):548-550.
9. Yao K, Shi GH, Wang XH, Xu D, Zhou PJ. Conversion from calcineurin inhibitor to sirolimus for renal function deterioration in kidney allograft recipients [in Chinese]. Chin J Organ Transplant. 2007;28(10):621-623.
10. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-470.
11. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol. 1999;10(1):167-181.
12. Paul LC. Chronic allograft nephropathy: An update. Kidney Int. 1999;56(3):783-793.
13. de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis. 2000;35(2):333-346.
14. Suwelack B, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant. 2004;4(4):655-662.
15. Schnuelle P, van der Heide JH, Tegzess A, et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol. 2002;13(2):536-543.
16. Smak Gregoor PJ, de Sevaux RG, Ligtenberg G, et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol. 2002;13(5):1365-1373.
17. Abramowicz D, Manas D, Lao M, V et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation. 2002;74(12):1725-1734.
18. Abramowicz D, Del Carmen Rial M, Vitko S, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol. 2005;16(7):2234-2240.
19. Mota A, Arias M, Taskinen EI, et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant. 2004;4(6):953-961.
20. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation. 2002;74(8):1070-1076.
21. Saber LT, Ikeda MY, Almeida JM. Posttransplantation conversion to sirolimus-based immunosuppression: a single center experience. Transplant Proc. 2007;39(10):3098-3100.
22. Shah N, Al-Khoury S, Afzali B, et al. Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors. Transplantation. 2006;81(8):1112-1118.
23. Al-Khoury S, Shah N, Afzali B, Covic A, Taylor J, Goldsmith D. Posttransplantation anaemia in adult and paediatric renal allograft recipients-Guy's Hospital experience. Nephrol Dial Transplant. 2006;21(7):1974-1980.
24. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34(6):429-455.
25. Kuypers DR, Ekberg H, Grinyo J, et al. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients. Clin Pharmacokinet. 2009;48(5):329-341.
26. Cattaneo D, Merlini S, Zenoni S, et al. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J Transplant. 2005;5(12):2937-2944.
27. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation. 2004;78(4):557-565.
28. Padi SS, Chopra K. Selective angiotensin II type 1 receptor blockade ameliorates cyclosporine nephrotoxicity. Pharmacol Res. 2002;45(5):413-420.
29. Castello L, Sainaghi PP, Bergamasco L, Letizia C, Bartoli E. Pathways of glomerular toxicity of cyclosporine-A: an in vitro study. J Physiol Pharmacol. 2005;56(4):649-660.
30. Stallone G, Infante B, Schena A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol. 2005;16(12):3755-3762.
31. Wali RK, Mohanlal V, Ramos E, et al. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant. 2007;7(6):1572-1583.
32. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant. 2006;6(3):514-522.
33. Ruiz JC, Campistol JM, Sanchez-Fructuoso A, et al. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimusbased treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant. 2006;21(11):3252-3257.